Literature DB >> 10768450

Thiazolidinediones: an update.

K Schoonjans1, J Auwerx.   

Abstract

Thiazolidinediones, which are being developed for the treatment of insulin resistance and type 2 diabetes mellitus, bind and activate peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates the expression of several genes involved in metabolism. This receptor controls adipocyte differentation, lipid storage, and insulin sensitisation. Besides metabolic activities, thiazolidinediones have effects as diverse as the control of host defence, cell proliferation, and tumorigenesis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10768450     DOI： 10.1016/S0140-6736(00)90002-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  34 in total

1.  Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.

Authors:  A J Krentz; C J Bailey; A Melander
Journal:  BMJ       Date:  2000-07-29

Review 2.  Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.

Authors:  J S Sidhu; J C Kaski
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

3.  The target for good glycemic control should be an Hb A(1C) concentration of less than 0.07.

Authors:  R Matz
Journal:  West J Med       Date:  2000-09

4.  A two-stage differential hydrogen deuterium exchange method for the rapid characterization of protein/ligand interactions.

Authors:  Michael J Chalmers; Scott A Busby; Bruce D Pascal; Mark R Southern; Patrick R Griffin
Journal:  J Biomol Tech       Date:  2007-09

5.  Synthesis and anti-obesity effects in vivo of Crotadihydrofuran C as a novel PPARγ antagonist from Crotalaria albida.

Authors:  Qin-Hu Sun; Yu Zhang; Gui-Xin Chou
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

Review 6.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

7.  Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.

Authors:  Stefan Frantz; Kai Hu; Julian Widder; Barbara Bayer; Catharina Clara Witzel; Isabel Schmidt; Paolo Galuppo; Jörg Strotmann; Georg Ertl; Johann Bauersachs
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 8.  Control of glycaemia: from molecules to men. Minkowski Lecture 2003.

Authors:  M Stumvoll
Journal:  Diabetologia       Date:  2004-04-28       Impact factor: 10.122

Review 9.  [Future targets in the treatment of type 2 diabetes].

Authors:  Harald Stingl; Michael Roden
Journal:  Wien Klin Wochenschr       Date:  2004-04-30       Impact factor: 1.704

10.  Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition.

Authors:  Andrew S Felts; Brianna S Siegel; Shiu M Young; Christopher W Moth; Terry P Lybrand; Andrew J Dannenberg; Lawrence J Marnett; Kotha Subbaramaiah
Journal:  J Med Chem       Date:  2008-07-30       Impact factor: 7.446
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.